Table 1.

Examples of studies with trastu-zumab in metastatic breast cancer

Trial design	Phase	ORR, %	TTP, median, mo	OS, median, mo
Trastuzumab monotherapy, first-line [17]	II	26	3.5	22.9
Trastuzumab monotherapy after chemotherapy [18]	II	21	3.1	13.0
Trastuzumab plus letrozole as first- or second-line therapy [29]	II	26	5.8	nr
Paclitaxel, carboplatin plus trastuzumab (every 3 weeks) [25]	II	65	9.9	27.6
Paclitaxel, carboplatin plus weekly trastuzumab [25]	II	81	13.8	38.4
Trastuzumab, docetaxel, and cisplatin [26]	II	79	9.9	nr
Trastuzumab, docetaxel, and carboplatin [26]	II	58	12.7	nr
Trastuzumab plus docetaxel [20] vs. docetaxel alone	II	61/34	11.7/6.1	31.2/22.7
Trastuzumab plus chemotherapy vs. chemotherapy alone [19]	III	50/32	7.4/4.6	22.1/18.4
Trastuzumab, paclitaxel plus carboplatin vs. trastuzumab plus paclitaxel [27]	III	52/36	nr	35.7/32.2
Anastrozole with trastuzumab vs. anastrozole alone [30]	III	20.3/6.8	4.8/2.4	28.5/23.9

ORR = Overall response rate; TTP = time to progression; OS = overall survival; mo = month; nr = not reached.